Interleukin 6 Dependence of Anti-DNA Antibody Production: Evidence for Two Pathways of Autoantibody Formation in Pristane-induced Lupus

Pristane induces a lupus-like syndrome in nonautoimmune mice characterized by the development of glomerulonephritis and lupus-associated autoantibodies. This is accompanied by overproduction of interleukin (IL)-6, a cytokine linked with autoimmune phenomena. The goal of this study was to evaluate the role of IL-6 in autoantibody production in pristane-induced lupus. BALB/cAn IL-6–deficient (−/−) and –intact (+/+) mice were treated with pristane or phosphate-buffered saline, and autoantibody production was evaluated. Pristane induced high levels of immunoglobulin (Ig)G anti-single-stranded DNA, –double-stranded (ds)DNA, and -chromatin antibodies in IL-6+/+, but not IL-6−/− mice by enzyme-linked immunosorbent assay. High titer IgG anti-dsDNA antibodies also were detected in sera from +/+, but not −/−, mice by Crithidia luciliae kinetoplast staining. The onset of IgG anti-dsDNA antibody production in +/+ mice occurred >5 mo after pristane treatment, well after the onset of nephritis, suggesting that these antibodies are not directly responsible for inducing renal disease. In contrast to anti-DNA, the frequencies of anti-nRNP/Sm and anti-Su antibodies were similar in pristane-treated IL-6−/− and IL-6+/+ mice. However, levels were higher in the +/+ group. These results suggest that IgG anti-DNA and chromatin antibodies in pristane-treated mice are strictly IL-6 dependent, whereas induction of anti-nRNP/Sm and Su autoantibodies is IL-6 independent. The IL-6 dependence of anti-DNA, but not anti-nRNP/Sm, may have implications for understanding the patterns of autoantibody production in lupus. Anti-DNA antibodies are produced transiently, mainly during periods of disease activity, whereas anti-nRNP/Sm antibody levels are relatively insensitive to disease activity. This may reflect the differential IL-6 dependence of the two responses.

[1]  B. Hahn Antibodies to DNA. , 1998, The New England journal of medicine.

[2]  M. Satoh,et al.  Influence of microbial stimulation on hypergammaglobulinemia and autoantibody production in pristane-induced lupus. , 1998, Clinical immunology and immunopathology.

[3]  S. Iwata,et al.  CD154/CD40 and CD70/CD27 interactions have different and sequential functions in T cell-dependent B cell responses: enhancement of plasma cell differentiation by CD27 signaling. , 1997, Journal of immunology.

[4]  P. Musiani,et al.  Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. , 1997, The American journal of pathology.

[5]  H. Nagafuchi,et al.  Autoreactive T cell clones from patients with systemic lupus erythematosus support polyclonal autoantibody production. , 1997, Journal of immunology.

[6]  M. Satoh,et al.  Autoantibodies to ribosomal P antigens with immune complex glomerulonephritis in SJL mice treated with pristane. , 1996, Journal of immunology.

[7]  R. Flavell,et al.  Autoimmune lpr/lpr mice deficient in CD40 ligand: spontaneous Ig class switching with dichotomy of autoantibody responses. , 1996, Journal of immunology.

[8]  W. Strober,et al.  The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response , 1996, The Journal of experimental medicine.

[9]  M. Retter,et al.  Both Sm and DNA are selecting antigens in the anti-Sm B cell response in autoimmune MRL/lpr mice. , 1996, Journal of immunology.

[10]  A. Kumar,et al.  Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[11]  S. Rudikoff,et al.  Interleukin 6 is essential for in vivo development of B lineage neoplasms , 1995, The Journal of experimental medicine.

[12]  A. Lanzavecchia,et al.  CD40 ligand‐independent B cell activation revealed by CD40 ligand‐deficient T cell clones: evidence for distinct activation requirements for antibody formation and B cell proliferation , 1995, European journal of immunology.

[13]  D. Malide,et al.  Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. , 1995, Human pathology.

[14]  A. Rolink,et al.  An interleukin‐6 transgene expressed in B lymphocyte lineage cells overcomes the T cell‐dependent establishment of normal levels of switched immunoglobulin isotypes , 1995, European journal of immunology.

[15]  J. Banchereau,et al.  Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes. , 1995, Journal of immunology.

[16]  C. Mohan,et al.  Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. , 1995, Journal of immunology.

[17]  M. Satoh,et al.  Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane , 1994, The Journal of experimental medicine.

[18]  D. Wofsy,et al.  Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. , 1994, The Journal of clinical investigation.

[19]  G. Ciliberto,et al.  Interleukin‐6 deficient mice are protected from bone loss caused by estrogen depletion. , 1994, The EMBO journal.

[20]  H. Nagafuchi,et al.  Constitutive expression of IL-6 receptors and their role in the excessive B cell function in patients with systemic lupus erythematosus. , 1993, Journal of immunology.

[21]  C. Franceschi,et al.  Increased cytokine production in mononuclear cells of healthy elderly people , 1993, European journal of immunology.

[22]  B. Kiberd Interleukin-6 receptor blockage ameliorates murine lupus nephritis. , 1993, Journal of the American Society of Nephrology.

[23]  C. Mohan,et al.  Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus , 1993, The Journal of experimental medicine.

[24]  R. Eisenberg,et al.  Overlap of the anti-Sm and anti-DNA responses of MRL/Mp-lpr/lpr mice. , 1993, Journal of immunology.

[25]  M. Alarcón‐Riquelme,et al.  Macrophage depletion decreases IgG anti‐DNA in cultures from (NZB · NZW)F1 spleen cells by eliminating the main source of IL‐6 , 1993, Clinical and experimental immunology.

[26]  T. Hirano,et al.  Abnormal distribution of IL-6 receptor in aged MRL/lpr mice: elevated expression on B cells and absence on CD4+ cells. , 1992, International immunology.

[27]  J. Williams,et al.  Elevation of interleukin-6 in response to a chronic inflammatory stimulus in mice: inhibition by indomethacin. , 1992, Blood.

[28]  M. Lohmann‐Matthes,et al.  Expansion and high proliferate potential of the macrophage system throughout life time of lupus‐prone NZB/W and MRL lpr/lpr mice. Lack of down‐regulation of extramedullar macrophage proliferation in the postnatal period , 1991, European journal of immunology.

[29]  S. Akira,et al.  Age-associated increase in interleukin 6 in MRL/lpr mice. , 1991, International immunology.

[30]  Y. Koishihara,et al.  Immunologic abnormality in NZB/W Fl mice. Thymus‐independent expansion of B cells responding to interleukin‐6 , 1990, Clinical and experimental immunology.

[31]  J. Renauld,et al.  Materials and Methods Briefdefinitive Report , 2022 .

[32]  M. Jourdan,et al.  Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. , 1990, Arthritis and rheumatism.

[33]  R. Eisenberg,et al.  Autoantibodies in chronic graft versus host result from cognate T-B interactions , 1990, The Journal of experimental medicine.

[34]  A. Muraguchi,et al.  Involvement of IL-6 in mesangial proliferative glomerulonephritis. , 1989, Journal of immunology.

[35]  D. Pisetsky,et al.  Induction of anti-double stranded DNA antibodies in normal mice by immunization with bacterial DNA. , 1989, Journal of immunology.

[36]  C. Fisher,et al.  Quantitation and IgG subclass distribution of antichromatin autoantibodies in SLE mice. , 1988, Clinical immunology and immunopathology.

[37]  P. Sehgal,et al.  Bacterial lipopolysaccharide (endotoxin) enhances expression and secretion of beta 2 interferon by human fibroblasts , 1987, The Journal of experimental medicine.

[38]  T. Hirano,et al.  TETSUYA TAGA , YOSHIKAZU KAWANISHI , 2003 .

[39]  D. Pisetsky,et al.  Antibodies to DNA. A perspective. , 1986, Arthritis and rheumatism.

[40]  R. Nordan,et al.  A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro. , 1986, Science.

[41]  R. Dziarski Preferential induction of autoantibody secretion in polyclonal activation by peptidoglycan and lipopolysaccharide. I. In vitro studies. , 1982, Journal of immunology.

[42]  R. Sontheimer,et al.  An immunofluorescence assay for double-stranded DNA antibodies using the Crithidia luciliae kinetoplast as a double-stranded DNA substrate. , 1978, The Journal of laboratory and clinical medicine.

[43]  P. Lambert,et al.  Features of systemic lupus erythematosus in mice injected with bacterial lipopolysaccharides: identificantion of circulating DNA and renal localization of DNA-anti-DNA complexes , 1977, The Journal of experimental medicine.

[44]  I. Mackay,et al.  Autoimmunity in a rural community. , 1972, Clinical and experimental immunology.

[45]  M. Satoh,et al.  Pristane induces high titers of anti-Su and anti-nRNP/Sm autoantibodies in BALB/c mice. Quantitation by antigen capture ELISAs based on monospecific human autoimmune sera. , 1995, Journal of immunological methods.

[46]  T. Hirano,et al.  Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[47]  V. Agnello,et al.  Polynucleotide immune complexes in serum and glomeruli of patients with systemic lupus erythematosus. , 1974, The American journal of pathology.